Crohn's & Colitis Congress 2020

Austin, Texas, US 23 January 2020 - 25 January 2020

Diffuse inflammation, stapled anastomosis may predict cuffitis risk

04 Mar 2020 by

Some patients with colitis are more likely than others to develop cuffitis after proctocolectomy with ileal pouch-anal anastomosis (IPAA), according to a retrospective study presented at the annual Crohn’s & Colitis Congress.

Diffuse inflammation, stapled anastomosis may predict cuffitis risk

04 Mar 2020

Ustekinumab proven effective for ulcerative colitis

21 Feb 2020 by

Treatment with ustekinumab has been shown to be effective for ulcerative colitis (UC) in a real-world setting, according to a recent study presented at the 2020 Crohn’s and Colitis Congress (CCC 2020).

Ustekinumab proven effective for ulcerative colitis

21 Feb 2020

Cigarette smoking still more rampant than vaping among IBD patients

21 Feb 2020 by

E-cigarette use remains low among adult patients with inflammatory bowel disease (IBD), and among these users, conventional cigarette smoking still remains prevalent, according to a recent study presented at the Crohn’s and Colitis Congress (CCC) 2020.

Cigarette smoking still more rampant than vaping among IBD patients

21 Feb 2020

PPIs may induce flares, nonremission status in CD patients

20 Feb 2020 by

Use of proton pump inhibitors (PPIs) among patients with Crohn’s disease (CD) could increase their risk of interval flare and is associated with nonremission status, according to a study presented at the 2020 Crohn’s and Colitis Congress (CCC 2020).

PPIs may induce flares, nonremission status in CD patients

20 Feb 2020

Timing and causes of death from inflammatory bowel diseases

20 Feb 2020 by

Patients with Crohn’s disease (CD) seem to die at a younger age than people without inflammatory bowel disease (IBD), while those with ulcerative colitis (UC) die later, according to a recent study presented at the Crohn’s and Colitis Congress (CCC) 2020.

Timing and causes of death from inflammatory bowel diseases

20 Feb 2020

ENTERPRET: Vedolizumab found to have positive exposure–response pattern in UC

20 Feb 2020 by

Among patients with ulcerative colitis (UC), vedolizumab serum concentrations in the fifth week after treatment initiation appear to have been higher in those who do vs do not show response in the sixth week, according to interim data from ENTERPRET study presented at the 2020 Crohn’s and Colitis Congress (CCC).

ENTERPRET: Vedolizumab found to have positive exposure–response pattern in UC

20 Feb 2020

How does a low-fat, high-fibre diet influence ulcerative colitis?

19 Feb 2020 by

A diet low in fat and high in fibre seems well tolerated in patients with ulcerative colitis, not contributing to increased inflammation while significantly increasing populations of Faecalibacterium prausnitzii, according to a study presented at the 2020 Crohn's & Colitis Congress.

How does a low-fat, high-fibre diet influence ulcerative colitis?

19 Feb 2020

Donor selection for FMT key to sustained UC remission

14 Feb 2020 by

Donor selection for faecal microbiota transplant (FMT) can make a difference to maintenance of long-term remission in patients with ulcerative colitis (UC), reveals a study presented at the 2020 Crohn's & Colitis Congress (CCC).

Donor selection for FMT key to sustained UC remission

14 Feb 2020

Ustekinumab dose escalation: An option for nonresponsive Crohn’s?

13 Feb 2020 by

Dose escalation of ustekinumab appears to be an effective option for Crohn’s disease (CD) patients with luminal and perianal manifestations who were nonresponsive to previous therapies, according to a study presented at the Crohn's & Colitis Congress (CCC) 2020.

Ustekinumab dose escalation: An option for nonresponsive Crohn’s?

13 Feb 2020

Mirikizumab may reduce bowel urgency in moderate-to-severe ulcerative colitis

13 Feb 2020 by

The humanized monoclonal antibody mirikizumab appears to reduce bowel movement urgency among patients with moderate to severely active ulcerative colitis (UC), according to a study presented at the Crohn’s and Colitis Congress 2020.

Mirikizumab may reduce bowel urgency in moderate-to-severe ulcerative colitis

13 Feb 2020